Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

OBJECTIVES: Sunitinib (a second-line chemotherapeutic agent that inhibits multiple kinases, including KIT and PDGFR) is widely used in imatinib-resistant patients with gastrointestinal stromal tumors (GISTs). However, diverse responses to sunitinib have been observed in the clinic. We aimed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Siyuan, Chen, Ping, Ji, Jiafu, Guo, Shanshan, Yu, Dapeng, Asakawa, Tetsuya, Zhou, Yu, Abe, Masanobu, Zong, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129330/
https://www.ncbi.nlm.nih.gov/pubmed/30224936
http://dx.doi.org/10.1155/2018/1368617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129330/
https://www.ncbi.nlm.nih.gov/pubmed/30224936
http://dx.doi.org/10.1155/2018/1368617

Ejemplares similares